Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Geriatrics

Volume 10 Supplement 1

de Senectute: Age and Health Forum

Open Access

Antiangiogenic therapy

  • T Avitabile1
BMC Geriatrics201010(Suppl 1):L4

https://doi.org/10.1186/1471-2318-10-S1-L4

Published: 19 May 2010

A brief look at AMD and developments which have completely subverted the therapeutic approach to patients affected by this disease.

New therapies available include: monoclonal antibody inhibitors of VEGF (Peptaganib, Bevacizumab, Ranibizumab) with the protocols currently in use and a brief reference to new anti-angiogenic therapies that include: decoy of VEGF receptor (VEGF Trap, Small Interfering RNA based therapies, Bevasiranib and AGN211745, Sirolimus) and the VEGF cascade of tyrosine kinase inhibitors (Vatalanib, Pazopanib, TG100801, TG101095, AG013958 and AL39324).

Authors’ Affiliations

(1)
Director department of Ophthalmology, Santa Marta Hospital, Azienda Policlinico-Vittorio Emanuele, University of Catania

Copyright

© Avitabile; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement